ATE285230T1 - Verwendung von chrysanthon-naturstoffen, die eine antiangiogene wirkung haben - Google Patents

Verwendung von chrysanthon-naturstoffen, die eine antiangiogene wirkung haben

Info

Publication number
ATE285230T1
ATE285230T1 AT01917464T AT01917464T ATE285230T1 AT E285230 T1 ATE285230 T1 AT E285230T1 AT 01917464 T AT01917464 T AT 01917464T AT 01917464 T AT01917464 T AT 01917464T AT E285230 T1 ATE285230 T1 AT E285230T1
Authority
AT
Austria
Prior art keywords
chrysanthone
natural substances
antiangiogenic effect
formula
compounds
Prior art date
Application number
AT01917464T
Other languages
English (en)
Inventor
Sergio Penco
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE285230T1 publication Critical patent/ATE285230T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
AT01917464T 2000-03-13 2001-03-12 Verwendung von chrysanthon-naturstoffen, die eine antiangiogene wirkung haben ATE285230T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000128A IT1317000B1 (it) 2000-03-13 2000-03-13 Uso di composti di origine naturale ad attivita' antiangiogenica.
PCT/IT2001/000120 WO2001068071A2 (en) 2000-03-13 2001-03-12 Use of natural chrysanthone compounds having antiangiogenic activity

Publications (1)

Publication Number Publication Date
ATE285230T1 true ATE285230T1 (de) 2005-01-15

Family

ID=11454525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01917464T ATE285230T1 (de) 2000-03-13 2001-03-12 Verwendung von chrysanthon-naturstoffen, die eine antiangiogene wirkung haben

Country Status (17)

Country Link
US (1) US6887883B2 (de)
EP (1) EP1274408B1 (de)
JP (1) JP2004500395A (de)
KR (1) KR20020081420A (de)
AT (1) ATE285230T1 (de)
AU (1) AU2001244537A1 (de)
CA (1) CA2401267A1 (de)
CZ (1) CZ20022761A3 (de)
DE (1) DE60107942T2 (de)
ES (1) ES2234827T3 (de)
HU (1) HUP0302472A2 (de)
IT (1) IT1317000B1 (de)
MX (1) MXPA02008952A (de)
PL (1) PL356931A1 (de)
PT (1) PT1274408E (de)
SK (1) SK11882002A3 (de)
WO (1) WO2001068071A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101094157B1 (ko) 2011-04-04 2011-12-14 임세규 식물생약재를 이용한 당뇨개선용 건강보조식품

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1225688A (zh) * 1996-05-20 1999-08-11 味之素株式会社 新型抗肿瘤类化合物及其制造方法
US6538103B1 (en) * 1998-07-14 2003-03-25 Bristol--Myers Squibb Company Lysine binding fragments of angiostatin

Also Published As

Publication number Publication date
MXPA02008952A (es) 2003-04-25
ES2234827T3 (es) 2005-07-01
US6887883B2 (en) 2005-05-03
CZ20022761A3 (cs) 2003-03-12
JP2004500395A (ja) 2004-01-08
WO2001068071A3 (en) 2002-06-06
PL356931A1 (pl) 2004-07-12
DE60107942T2 (de) 2005-12-08
US20030149068A1 (en) 2003-08-07
CA2401267A1 (en) 2001-09-20
AU2001244537A1 (en) 2001-09-24
DE60107942D1 (de) 2005-01-27
EP1274408A2 (de) 2003-01-15
IT1317000B1 (it) 2003-05-26
KR20020081420A (ko) 2002-10-26
HUP0302472A2 (hu) 2003-12-29
ITRM20000128A1 (it) 2001-09-13
PT1274408E (pt) 2005-03-31
WO2001068071A2 (en) 2001-09-20
SK11882002A3 (sk) 2003-02-04
EP1274408B1 (de) 2004-12-22
ITRM20000128A0 (it) 2000-03-13

Similar Documents

Publication Publication Date Title
DK1200418T3 (da) Nematodicide trifluorbutener
ATE288431T1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60319066D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
BG108181A (bg) Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7
EA200401232A1 (ru) Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
ATE297188T1 (de) Stabilisierte ascorbinsäure-lösungen
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
TR200401669T1 (tr) Neoplastik hastalıkların tedavisi için metarix-metalloproteinazları önleyen kompozisyon.
EA200600778A1 (ru) 1,3-диметилбутилкарбоксанилиды для борьбы с нежелательными микроорганизмами
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
PT1140113E (pt) Utilizacao de bisfosfonatos para profilaxia e tratamento de processos infecciosos
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
DK1204659T3 (da) Serotonerge benzofuraner
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
EA200200948A1 (ru) Лечение псориаза
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE285230T1 (de) Verwendung von chrysanthon-naturstoffen, die eine antiangiogene wirkung haben
DK0891326T3 (da) Nye D-vitaminanaloger
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
ATE242763T1 (de) Methoximinophenylessigsäureamide
DE59809344D1 (de) Disubstituierte biphenyloxazoline
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274408

Country of ref document: EP

REN Ceased due to non-payment of the annual fee